Profile data is unavailable for this security.
About the company
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
- Revenue in USD (TTM)0.00
- Net income in USD-18.70m
- Incorporated2014
- Employees12.00
- LocationCocrystal Pharma Inc19805 N Creek PkwyBOTHELL 98011-8251United StatesUSA
- Phone+1 (786) 459-1831
- Fax+1 (302) 636-5454
- Websitehttps://www.cocrystalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | 7.10m | -39.43m | 19.96m | 22.00 | -- | 0.3866 | -- | 2.81 | -0.9598 | -0.9598 | 0.1728 | 1.25 | 0.0798 | -- | -- | 244,862.10 | -44.28 | -41.24 | -55.51 | -46.49 | -- | -- | -555.23 | -1,774.39 | -- | -121.12 | 0.0399 | -- | -- | -- | -3.77 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -27.73m | 20.42m | 8.00 | -- | 1.58 | -- | -- | -4.77 | -4.77 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -114.20 | -95.57 | -159.68 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| GlycoMimetics Inc | 10.00k | -39.74m | 20.43m | 35.00 | -- | 1.80 | -- | 2,042.85 | -0.6165 | -0.6165 | 0.0002 | 0.1764 | 0.0003 | -- | 0.0836 | 285.71 | -115.34 | -43.60 | -136.58 | -47.82 | -- | -- | -397,350.50 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Kairos Pharma Ltd | 0.00 | -2.74m | 20.55m | -- | -- | 6.17 | -- | -- | -0.2279 | -0.2279 | 0.00 | 0.2594 | 0.00 | -- | -- | -- | -92.10 | -- | -264.70 | -- | -- | -- | -- | -- | -- | -2.61 | 0.0409 | -- | -- | -- | -72.57 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -350.57m | 20.95m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.44m | 21.93m | 4.00 | -- | 8.50 | -- | -- | -1.09 | -1.09 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -250.15 | -- | -498.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 9.78m | -65.09m | 22.14m | 100.00 | -- | 0.3074 | -- | 2.26 | -1.71 | -1.71 | 0.2567 | 1.88 | 0.0687 | -- | -- | 97,790.00 | -45.72 | -48.32 | -52.52 | -54.03 | -- | -- | -665.56 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Pieris Pharmaceuticals Inc | 1.35m | -15.95m | 22.15m | 46.00 | -- | 1.36 | -- | 16.38 | -12.61 | -12.61 | 1.06 | 12.32 | 0.0338 | -- | 1.91 | 29,391.30 | -39.93 | -28.41 | -68.21 | -39.69 | -- | -- | -1,179.96 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Pulmatrix Inc | 10.01m | -9.66m | 22.35m | 22.00 | -- | 2.05 | -- | 2.23 | -2.64 | -2.64 | 2.74 | 2.99 | 0.4145 | -- | 23.16 | 454,772.70 | -40.00 | -46.91 | -44.64 | -58.12 | -- | -- | -96.51 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Cocrystal Pharma Inc | 0.00 | -18.70m | 22.38m | 12.00 | -- | 1.76 | -- | -- | -1.84 | -1.84 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -76.57 | -50.94 | -83.17 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.83m | 17.00 | -- | 2.10 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 23.36m | 11.00 | -- | 2.49 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.74m | 23.96m | 25.00 | -- | 0.7112 | -- | -- | -2.51 | -2.51 | 0.00 | 4.05 | 0.00 | -- | -- | 0.00 | -43.08 | -45.97 | -47.69 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Ibio Inc | 175.00k | -14.36m | 24.12m | 16.00 | -- | 1.28 | -- | 137.85 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Athira Pharma Inc | 0.00 | -109.22m | 24.68m | 65.00 | -- | 0.4311 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Cocrystal Pharma Inc's reporting currency: US Dollar USD
6.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 275.66k | 2.71% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 130.03k | 1.28% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 73.75k | 0.73% |
| Geode Capital Management LLCas of 30 Sep 2024 | 66.26k | 0.65% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 59.30k | 0.58% |
| G1 Execution Services LLCas of 30 Sep 2024 | 37.80k | 0.37% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 20.54k | 0.20% |
| Parallel Advisors LLCas of 30 Sep 2024 | 15.23k | 0.15% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 14.09k | 0.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 12.17k | 0.12% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
